Compare Charles River Laboratories Intl. Inc (CRL) vs ProShares UltraPro QQQ ETF (TQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs ProShares UltraPro QQQ ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while ProShares UltraPro QQQ ETF trades at $81.4 (market cap $38.74B). The key difference: ProShares UltraPro QQQ ETF is far larger — about 2.7× Charles River Laboratories Intl. Inc's market cap, and ProShares UltraPro QQQ ETF is more actively traded (65,384,797 versus 1,176,885). Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and ProShares UltraPro QQQ ETF for 24 Days on average.
| CRL | TQQQ | |
|---|---|---|
Market Cap | $14.23B | $38.74B |
Volume | 1,176,885 | 65,384,797 |
Sector | Health | Leveraged / Inverse |
52-Week High | $310.77 | $87.22 |
52-Week Low | $149.93 | $37.89 |
Typical Hold Time | 33 Days | 24 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
TQQQ trades at $81.16, down 2.92% on the day, with technical indicators showing a bullish overall signal despite recent selling pressure. The leveraged ETF structure amplifies both gains and losses, with recent news highlighting hidden costs beyond the stated 0.82% expense ratio. Support levels are established at $78 and $76, while resistance sits at $83 and $85.
The outlook for TQQQ remains tied to Nasdaq-100 performance and tech sector momentum, though volatility decay and financing costs present significant long-term risks. Current technical positioning suggests potential for near-term upside if support holds, but investors should be cautious of amplified losses during market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About ProShares UltraPro QQQ ETF
TQQQ is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the Nasdaq-100 Index. It is one of the most liquid and actively traded instruments in the market, designed for sophisticated traders to amplify short-term bullish exposure to large-cap non-financial growth stocks, predominantly in the technology and communication sectors.
Read more on TQQQ →
